Pacific Edge Limited
9
4
4
3
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 60/100
11.1%
1 terminated/withdrawn out of 9 trials
75.0%
-11.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 3 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (9)
Bladder Cancer Screening Trial
Role: collaborator
Efficacy and Utility of Cxbladder Tests in Hematuria Patients
Role: lead
Detection and Risk Stratification in Veterans Presenting With Microscopic Hematuria
Role: lead
Longitudinal Bladder Cancer Study for Tumour Recurrence
Role: lead
Study to Assess the Impact of the Urine Test Cxbladder Triage Plus on the Number of Cystoscopies Performed on Patients With Invisible Blood in Their Urine.
Role: lead
STRATA: Safe Testing of Risk for AsymptomaTic MicrohematuriA
Role: lead
Detection of Disease in the Upper Tract
Role: lead
The Cxbladder Monitoring Study
Role: lead
The Cxbladder Rule-out of Recurrent Urothelial Carcinoma
Role: collaborator
All 9 trials loaded